Art. 36 Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 20…

In forcesince 31 Mar 2004cited 8×

If an applicant withdraws an application for a marketing authorisation submitted to the Agency before an opinion has been given on the application, the applicant shall communicate its reasons for doing so to the Agency. The Agency shall make this information publicly accessible and shall publish the assessment report, if available, after deletion of all information of a commercially confidential nature.

  • Ordonnance du président du Tribunal du 20 juillet 2016. MSD Animal Health Innovation GmbH et Intervet international BV contre Agence européeDecision

    … of an MA file for a veterinary medicinal product, the applicants’ claim that those texts — namely, inter alia, Articles 36, 37(3), 38(3), 57(1), point l, 57(2), 76 and 80 of Regulation No 726/2004 and Articles 13 and 76 of Directive …

    20 Jul 2016 · 62015TO0729

  • Judgment of the General Court (Second Chamber, Extended Composition) of 5 February 2018. Pari Pharma GmbH v European Medicines Agency.Decision

    Regulation No 726/2004 requires the EMA, in Article 11, Article 13(3), Article 36, Article 38(3) and Article 57(1) and (2) thereof, to publish three documents, namely the EPAR, a summary of the characteristics of the medicinal products …

    5 Feb 2018 · 62015TJ0235

  • Judgment of the General Court (Second Chamber) of 5 February 2018. PTC Therapeutics International Ltd v European Medicines Agency.Decision

    Regulation No 726/2004 requires the EMA, in Article 11, Article 13(3), Article 36, Article 38(3) and Article 57(1) and (2) thereof, to publish three documents, namely the European Public Assessment Report (‘the EPAR’), a summary of the …

    5 Feb 2018 · 62015TJ0718

  • Order of the Vice-President of the Court of 1 March 2017. European Medicines Agency (EMA) v MSD Animal Health Innovation GmbH and Intervet iDecision

    The existence of such a presumption follows from the system established by the sector-specific legislation applicable to marketing authorisation for veterinary medicinal products, in particular by Article 36, Article 37(3), Article 38(3) …

    1 Mar 2017 · 62016CO0512

  • Judgment of the General Court (Second Chamber) of 5 February 2018. MSD Animal Health Innovation GmbH and Intervet international BV v EuropeaDecision

    Regulation No 726/2004 requires the EMA, in Article 11, Article 13(3), Article 36, Article 38(3) and Article 57(1) and (2) thereof, to publish three documents, namely the European Public Assessment Report (‘the EPAR’), a summary of the …

    5 Feb 2018 · 62015TJ0729

  • Regulation (EU) 2019/5Lawamends

  • Judgment of the General Court (Second Chamber) of 25 September 2018. Amicus Therapeutics UK Ltd and Amicus Therapeutics, Inc. v European MedDecision

    Articles 11, 13(3), 36, 38(3) and 57(1) and (2) of Regulation No 726/2004 require the EMA to publish three documents, namely the European Public Assessment Report (EPAR), a summary of the characteristics of the medicinal products concerned …

    25 Sep 2018 · 62017TJ0033

  • Opinion of Advocate General Hogan delivered on 11 September 2019. MSD Animal Health Innovation GmbH and Intervet International BV v EuropeanDecision

    The wording of the first paragraph of Article 73 of Regulation 726/2004 is broad and unqualified. The fact that certain information has to be published proactively [See Article 35(6), Article 36, Article 37(3) and Article 38(2) and (3) of …

    11 Sep 2019 · 62018CC0178